Vericiguat

Active substance
Vericiguat
Domain
Cardiovascular diseases
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Other medication for cardiovascular diseases
Extended indication
Hartfalen met verminderde ejectiefractie (HFrEF)

1. Product

Manufacturer
Bayer
Mechanism of action
Other, see general comments
Route of administration
Oral
Therapeutical formulation
Tablet
Budgetting framework
Extramural (GVS)
Additional comments
Stimulator van het soluble guanylate cyclase (sGC) enzym.

2. Registration

Registration route
Centralised (EMA)
Type of trajectory
Normal trajectory
Submission date
July 2020
Expected Registration
August 2021
Orphan drug
No
Registration phase
Clinical trials

3. Therapeutic value

Current treatment options
Patiënten met HErEF ontvangen veel verschillende soorten medicatie. Voorbeelden hiervan zijn: ''81% of the patients were treated with loop diuretics, 84% with renin-angiotensin-system (RAS) inhibitors, 86% with β-blockers, 56% with mineralocorticoid-receptor antagonists (MRA), and 5% with If-channel inhibition.'' (Brunner-La Rocca et al. , 2019)
Therapeutic value
No judgement
Substantiation
Patiënten met HErEF ontvangen al veel medicatie, vericiguat zal naast deze medicatie voorgeschreven worden.
Frequency of administration
1 times a day
Dosage per administration
2,5, 5 of 10 mg
References
NCT02861534 Brunner-La Rocca et al. (2019). Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 7(1), 13-21. doi: 10.1016/j.jchf.2018.10.010

4. Expected patient volume per year

Patient volume

< 3,000

Market share is generally not included unless otherwise stated.

Additional comments
Patiënten met HErEF ontvangen veel verschillende soorten medicatie, Vericiguat zal hier nog bovenop komen. Het patiëntaantal zal naar verwachting niet hoger liggen dan 3.000 patiënten per jaar (vergelijkbaar met entresto).

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
No

9. Other information

There is currently no futher information available.